JO
GLMD icon

John Overdeck’s Galmed Pharmaceuticals GLMD Stock Holding History

John Overdeck’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,022
Closed -$39.3K – 5205
2026
Q1 		$39.3K Sell
10,022
-3,996
-29% -$21.6K ﹤0.01% 4474
2025
Q4 		$84.2K Buy
14,018
+11,368
+429% +$106K ﹤0.01% 3872
2025
Q3 		$29.3K Buy
+2,650
New +$34K ﹤0.01% 3574
2024
Q1 		– Sell
-245
Closed -$10.7K – 3150
2023
Q4 		$10.7K Sell
245
-75
-23% -$2.86K ﹤0.01% 3083
2023
Q3 		$19K Buy
+320
New +$34K ﹤0.01% 2874
2021
Q2 		– Sell
-12
Closed -$57K – 4237
2021
Q1 		$57K Buy
+12
New +$66.4K ﹤0.01% 3736

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

John Overdeck's GLMD Position: Q2 2026 in Review

John Overdeck sold out of Galmed Pharmaceuticals (GLMD) in Q2 2026, closing a stake of 10,022 shares — an estimated $39.3K sold.

John Overdeck first reported a position in GLMD in Q1 2021 and held it in 6 quarters. The position peaked at $84.2K in Q4 2025. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • John Overdeck reported no remaining Galmed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 10,022 Galmed Pharmaceuticals shares in Q2 2026, an estimated $39.3K.
  • John Overdeck first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • John Overdeck's Galmed Pharmaceuticals position peaked at $84.2K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.